cobicistat

Cobicistat is a small molecule pharmacokinetic enhancer used in the treatment of human immunodeficiency virus (HIV) infection. It acts as a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms, specifically CYP3A4, CYP3A5, and CYP3A7. By inhibiting these enzymes, cobicistat increases the systemic exposure of coadministered antiretroviral agents that are metabolized by CYP3A—most notably atazanavir and darunavir—allowing for more effective HIV therapy at lower doses. Cobicistat itself has no anti-HIV activity and is not an antiviral agent; its role is solely to boost the levels of other HIV medications. It was developed as an alternative to ritonavir with improved selectivity and fewer off-target drug interactions[1][2][3][6].

Brand names

Tybost

Other names

COBI